21. Februar 2024
Published by Paul Wolfrom on 21. Februar 2024
Categories

LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V

Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further […]
Do you like it?0
Read more
1. Februar 2024
Published by Paul Wolfrom on 1. Februar 2024
Categories

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raise to $40 Million

Schlieren (Zurich), February 01, 2024 – LimmaTech Biologics today announced a second closing of its Series A financing, raising an additional USD 3 million from new […]
Do you like it?0
Read more